BioCentury
ARTICLE | Clinical News

Tecemotide discontinued in NSCLC

September 13, 2014 1:33 AM UTC

Oncothyreon Inc. (NASDAQ:ONTY) said in an SEC filing that partner Merck KGaA (Xetra:MRK) will stop development of tecemotide ( L-BLP25) as a monotherapy for non-small cell lung cancer (NSCLC). The compound was in Phase III testing.

Last month, tecemotide missed the primary endpoint in a Japanese Phase I/II trial in the indication. Shares of the biotech fell $0.48 (17%) to $2.30 that day (see BioCentury Extra, Aug. 19). ...